Evidence map›Paper›PMID 42193988›Full record

ArticleBiomolecules2026

Soluble E-Cadherin as a New Prognostic Biomarker Able to Predict Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma.

Paola Carolina Rabesquini Marcelino da Silva, Igor Cerejo Tavares da Silva de Almeida, Joaquim Gasparini Dos Santos, Leonardo Jun Otuyama, Cadiele Oliana Reichert, Hebert Fabrício Culler, Nélio Cézar de Aquino, Lilian de Souza França, Sheila Aparecida Coelho da Siqueira, Renata de Oliveira Costa and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Paola Carolina Rabesquini Marcelino da SilvaLaboratory of Medical Investigation in Pathogenesis and Directed Therapy in Immuno-Onco-Hematology (LIM-31), Faculty of Medicine, University of Sao Paulo, Sao Paulo 05430-000, Brazil.
Igor Cerejo Tavares da Silva de AlmeidaLaboratory of Medical Investigation in Pathogenesis and Directed Therapy in Immuno-Onco-Hematology (LIM-31), Faculty of Medicine, University of Sao Paulo, Sao Paulo 05430-000, Brazil.ORCID 0000-0002-6266-4596
Joaquim Gasparini Dos SantosDepartment of Hematology, Hemotherapy & Cell Therapy, Faculty of Medicine, University of Sao Paulo, Sao Paulo 05430-000, Brazil.
Leonardo Jun OtuyamaDepartment of Hematology, Hemotherapy & Cell Therapy, Faculty of Medicine, University of Sao Paulo, Sao Paulo 05430-000, Brazil.
Cadiele Oliana ReichertLaboratory of Medical Investigation in Pathogenesis and Directed Therapy in Immuno-Onco-Hematology (LIM-31), Faculty of Medicine, University of Sao Paulo, Sao Paulo 05430-000, Brazil.
Hebert Fabrício CullerLaboratory of Medical Investigation in Pathogenesis and Directed Therapy in Immuno-Onco-Hematology (LIM-31), Faculty of Medicine, University of Sao Paulo, Sao Paulo 05430-000, Brazil.
Nélio Cézar de AquinoLaboratory of Medical Investigation in Pathogenesis and Directed Therapy in Immuno-Onco-Hematology (LIM-31), Faculty of Medicine, University of Sao Paulo, Sao Paulo 05430-000, Brazil.
Lilian de Souza FrançaLaboratory of Medical Investigation in Pathogenesis and Directed Therapy in Immuno-Onco-Hematology (LIM-31), Faculty of Medicine, University of Sao Paulo, Sao Paulo 05430-000, Brazil.
Sheila Aparecida Coelho da SiqueiraDepartment of Pathology, Faculty of Medicine, University of Sao Paulo, Sao Paulo 05430-000, Brazil.
Renata de Oliveira CostaDepartment of Hematology, Faculdade de Ciências Médicas de Santos, Fundação Lusíada, Santos 11050-071, Brazil.
Vanderson RochaLaboratory of Medical Investigation in Pathogenesis and Directed Therapy in Immuno-Onco-Hematology (LIM-31), Faculty of Medicine, University of Sao Paulo, Sao Paulo 05430-000, Brazil.
Sérgio Paulo BydlowskiDepartment of Hematology, Hemotherapy & Cell Therapy, Faculty of Medicine, University of Sao Paulo, Sao Paulo 05430-000, Brazil.ORCID 0000-0002-7582-5942
Débora LevyLaboratory of Medical Investigation in Immunology and Histocompatibility (LIM-19), Faculty of Medicine, University of Sao Paulo, Sao Paulo 05430-000, Brazil.ORCID 0000-0001-7492-997X
Juliana PereiraLaboratory of Medical Investigation in Pathogenesis and Directed Therapy in Immuno-Onco-Hematology (LIM-31), Faculty of Medicine, University of Sao Paulo, Sao Paulo 05430-000, Brazil.ORCID 0000-0002-0655-2821
Luís Alberto de Pádua Covas LageLaboratory of Medical Investigation in Pathogenesis and Directed Therapy in Immuno-Onco-Hematology (LIM-31), Faculty of Medicine, University of Sao Paulo, Sao Paulo 05430-000, Brazil.ORCID 0000-0002-9228-3276

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antigens, CDBiomarkers, TumorCadherinsLymphoma, Large B-Cell, DiffuseAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinFemaleHumansIntercellular Adhesion Molecule-1Longitudinal StudiesMaleMiddle AgedAntigens, CDBiomarkers, TumorCadherinsCyclophosphamideDoxorubicinIntercellular Adhesion Molecule-1PrednisoneP-SelectinR-CHOP protocolRituximabVascular Cell Adhesion Molecule-1Vincristinecancer biomarkerscell adhesion moleculesdiffuse large B-cell lymphomaprognosissE-cadherinsICAM-1sP-selectinsVCAM-1

Identifiers

PMID42193988
PMCPMC13204984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.